Regado Biosciences, Inc., a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, today announced the completion of a $40 million Series D financing. The round, led by new investor Edmond de Rothschild Investment Partners, part of The LCF Rothschild Group, was joined by existing investors Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors.
Proceeds from the financing will be used to continue the development of Regado's lead program in arterial thrombosis, REG1, with specific emphasis on the completion of the phase 2b (RADAR) trial currently underway. Additionally, the funding will support the completion of the ongoing phase 1 trial with the Company's second product candidate, REG2, focused on venous thrombosis as well as the identification of a clinical candidate therapeutic aptamer/active control agent pair in the REG-AP platelet adhesion/activation inhibitor discovery program.
Raphael Wisniewski, Partner at Edmond de Rothschild Investment Partners, said, "Since the introduction of the first antithrombotic therapy, physicians have faced the need to prevent harmful clots while allowing healing clots to form and develop normally. Regado's exclusive paired aptamer/active control agent technology represents an optimized solution to this dilemma. We and the other investors are convinced of the large unmet medical need for this technology, which represents a novel approach to the practice of personalized medicine in the cardiovascular acute and sub-acute care market."
David J. Mazzo, Ph.D., President and CEO of Regado Biosciences, commented, "We are extremely pleased to welcome Edmond de Rothschild Investment Partners as an investor in the Company. Regado has a comprehensive antithrombotic pipeline, which reflects the company's expertise in the discovery and development of therapeutic aptamers with active control agents for application in the areas of both arterial and venous thrombosis. Our innovative products represent a simple and elegant approach to addressing a key unmet medical need in a market that, taken in aggregate, today exceeds $20 billion worldwide."
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke